Ara 290 vs BPC-157: Comparing the Indexed Record
Ara 290 and BPC-157 appear together in search far more often than they appear together in published methodology. That gap is the useful part.
Side-by-side research profile
| Parameter | Ara 290 | BPC-157 |
|---|---|---|
| PubMed indexed records | 24 | 228 |
| Registered studies (ClinicalTrials.gov) | 4 | 4 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
Ara 290 in the indexed record
Searching Ara 290 against the PubMed index returns 24 records, a limited evidence base, alongside 4 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Brain Behav Immun, Mol Pain, Peptides, spanning 2014–2022.
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception — Peptides, 2016. PMID: 26774587
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression — Brain Behav Immun, 2022. PMID: 34343617
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets — Transplantation, 2016. PMID: 26683514
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response — Mol Pain, 2014. PMID: 24529189
BPC-157 in the indexed record
Searching BPC-157 against the PubMed index returns 228 records, a moderate evidence base, alongside 4 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Altern Ther Health Med, Cell Tissue Res, Curr Rev Musculoskelet Med, spanning 2019–2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021. PMID: 34324435
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025. PMID: 40756949
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res, 2019. PMID: 30915550
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel), 2025. PMID: 40005999
How the literature differs
The indexed record is not symmetrical between these two compounds. BPC-157 carries 204 more indexed records than Ara 290, which means published methodology, characterisation data and replication attempts are more readily located for BPC-157. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (4 vs 4) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
Ara 290 and BPC-157 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Ara 290 describes conditions validated for Ara 290: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to BPC-157 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Selecting between them for a study design
Ara 290 and BPC-157 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (BPC-157) generally offers more methodological precedent.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Which of Ara 290 or BPC-157 has more published research?
BPC-157, with 228 indexed PubMed records against 24.
Are Ara 290 and BPC-157 the same compound?
No. They are structurally distinct research compounds with separate literature records — 24 indexed records for Ara 290 and 228 for BPC-157.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- BPC-157 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.